DOSE MODIFICATION GUIDELINES FOR PERIPHERAL NEUROPATHY*
For neuropathic pain and/or peripheral sensory or motor neuropathy related to VELCADE®
Patients with preexisting neuropathy should be treated with VELCADE only after careful risk-benefit assessment
DOSE MODIFICATION GUIDELINES TO MANAGE OTHER ADVERSE EVENTS
For other adverse events, VELCADE therapy should be withheld at the onset of any grade 3 nonhematologic or grade 4 hematologic toxicity with the exception of peripheral neuropathy, as discussed above
|
|
Once the symptoms of toxicity have resolved, therapy may be
reinitiated at a 25% reduced dose
|
*Based on dose modifications in phase 2 and 3 multiple myeloma studies.
†National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. December 2003.11
Please
click here to view additional important safety information.
For full Prescribing Information
click here. (pdf) (74KB)
For further information about VELCADE® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).
